National trends in prescription drug expenditures and projections for 2023
This observation is consistent with evidence demonstrating reductions in high-sensitivity CRP (hs-CRP), highlighting a broader anti-inflammatory and anti-atherosclerotic profile of this drug class ( Beyond these established biomarkers, emerging molecular signatures such as circulating microRNAs (miRs) are increasingly recognized as sensitive indicators of early atherosclerotic changes and may provide additional insight into GLP-1RA-mediated vascular effects
(2019) The Discovery and Development of Liraglutide and Semaglutide
thelancet.com/journals/lance LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial @TheLancet @LillyTrials #Retatrutide thelancet.com/journals/lance LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial @TheLancet @LillyTrials #Retatrutide Excelente
